Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?!

Another of our deep-in-the-weeds theranostic webinars in conjunction with our friends at ProsTiC, and the Prostate Cancer Foundation. This one focussed on Terbium-161, a very exciting new option in metastatic prostate cancer. Your hosts are Dr Renu Eapen and Professor Michael Hofman, with Dr Howard Soule and Dr Andrea Miyahira from the Prostate Cancer Foundation. Special guests include Dr James Buteau (Peter Mac, Melbourne, Australia), Dr Alin Chirindel (Universitätsspital Basel), Prof Dr Samer Ezziddin (Saarland University Hospital, Germany) and Prof. Cristina Müller (Paul Scherrer Institute, Switzerland)

Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25.

A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!!

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer.

Exclusive discussion with Arun Azad and Michael Hofman to celebrate Arun'z presentation of UpFront PSMA at ESMO24 today. Simultaneous publication in Lancet Oncology. This is a Themed Podcast supported by our Silver Partners, Novartis.

Educational and entertaining GU Cast Conference Highlights from the ProsTIC24 Preceptorship in Melbourne.

We loved having Neil Fleshner in the studio!!

Another one of our PSMA theranostics webinars in collaboration with ProsTIC, the PCF, and the International Cancer Imaging Society. Fabulous deep dive into earlier use of LuPSMA